Search hospitals
>
Minnesota
>
Minneapolis
Mercy Hospital
Claim this profile
Minneapolis, Minnesota 55433
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
393 reported clinical trials
15 medical researchers
Summary
Mercy Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Mercy Hospital is involved with conducting 393 clinical trials across 547 conditions. There are 15 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Area of expertise
Breast Cancer
Mercy Hospital has run 108 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Mercy Hospital has run 84 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
David M. King
Park Nicollet Clinic - Saint Louis Park
9 years of reported clinical research
Daniel M. Anderson
Abbott-Northwestern Hospital
7 years of reported clinical research
Yan Ji
Regions Hospital
2 years of reported clinical research
Pamala A. Pawloski
Park Nicollet Clinic - Saint Louis Park
6 years of reported clinical research
Clinical Trials running at Mercy Hospital
Lung Cancer
Breast Cancer
Prostate Cancer
Esophageal cancer
Bladder Cancer
Colorectal Cancer
Breast cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mercy Hospital?
Mercy Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Mercy Hospital is involved with conducting 393 clinical trials across 547 conditions. There are 15 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Mercy Hospital located?
**Mercy Hospital Location and Directions:** - **Address:** 4050 Coon Rapids Blvd, Coon Rapids, MN 55433. - **Directions:** From Interstate 694, take the Hwy 252 North exit. Follow Hwy 252 to Interstate 610 East, then continue on Hwy 10 to reach the hospital.
Who should I call to ask about financial aid or insurance network?
For Mercy Hospital's financial assistance, please call 410-951-1700. For general billing and insurance inquiries, contact the customer service team at 855-420-7900.
What insurance does Mercy Hospital accept?
Mercy Hospital accepts a wide range of insurance plans such as MercyCare, Aetna, Blue Cross Blue Shield, ChoiceCare, Humana, Health Alliance, and Meridian among others. It's important to verify with your insurance provider as accepted plans can vary by hospital location. Note that some insurance plans may be considered out-of-network, making patients responsible for total billed charges.
What awards or recognition has Mercy Hospital received?
Mercy Hospital in Minneapolis, Minnesota, is renowned for its commitment to patient safety, quality care, and research. It has been recognized by the Minnesota Department of Health for excellence in patient safety and named among the 50 Top Cardiovascular Hospitals®. The hospital holds accreditation from The Joint Commission and certification as a Primary Stroke Center by DNV, with Mercy Research leading in community health system-based research across multiple therapeutic areas.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.